Study summary

The first drug for bronchiectasis cut flare-ups by about a fifth

ASPEN trial (brensocatib) · 1,721 people, phase 3 · Published April 2025, New England Journal of Medicine; FDA approved August 2025

0.79rate ratio for flare-ups vs placebo (10 mg)

What was tested

Brensocatib, a once-daily pill that blocks DPP-1, an enzyme that arms neutrophils (inflammatory white cells) in the airways, at 10 mg or 25 mg, against placebo.

What they found

What it means

The first approved treatment for non-cystic fibrosis bronchiectasis, targeting the inflammation behind it.

N Engl J Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.